Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score

Sung Gwe Ahn, Hak Min Lee, Hak Woo Lee, Seung Ah Lee, Se Ra Lee, Sun Hee Leem, Jeong Joon, In Sun Chu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The Oncotype DX® recurrence score (RS) predictor has been clinically utilized to appropriately select adjuvant chemotherapy for patients with estrogen receptor (ER)-positive early breast cancer. However, the selection of chemotherapy for patients with intermediate RSs remains controversial. We assessed the prognostic value of a 70-gene signature (70GS) among patients with ER-positive breast cancer and intermediate RSs. In addition, we sought to identify genes associated with poor 70GS scores based on gene expression profiling (GEP). GEP was performed using gene expression data from 186 patients with ER-positive breast cancer. The RS and 70GS score were calculated on the basis of GEP. Among 186 patients, 82 ER-positive patients with intermediate RSs were identified. These patients were stratified by 70GS, overall survival (OS) significantly differed according to 70GS (p = 0.013). In a supervised hierarchical analysis according to 70GS, the expression of several representative genes for cell proliferation was significantly higher in the poor 70GS cluster than in the good 70GS cluster. Furthermore, among these patients, FOXM1, AURKA, AURKB, and BIRC5 displayed prognostic significance for OS. In conclusion, 70GS can help to discriminate survival differences among ER-positive patients with intermediate RSs. FOXM1, AURKA, AURKB, and BIRC5, are associated with poor 70GS scores.

Original languageEnglish
Pages (from-to)23685-23699
Number of pages15
JournalInternational journal of molecular sciences
Volume14
Issue number12
DOIs
Publication statusPublished - 2013 Dec 4

Fingerprint

estrogens
breast
Estrogen Receptors
genes
discrimination
Genes
cancer
signatures
Breast Neoplasms
Recurrence
gene expression
Gene Expression Profiling
Aurora Kinase A
Gene expression
Multigene Family
Chemotherapy
Survival
chemotherapy
Estrogens
Adjuvant Chemotherapy

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Ahn, Sung Gwe ; Lee, Hak Min ; Lee, Hak Woo ; Lee, Seung Ah ; Lee, Se Ra ; Leem, Sun Hee ; Joon, Jeong ; Chu, In Sun. / Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score. In: International journal of molecular sciences. 2013 ; Vol. 14, No. 12. pp. 23685-23699.
@article{4171afb5727e487eb669a3c2e98bd0ec,
title = "Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score",
abstract = "The Oncotype DX{\circledR} recurrence score (RS) predictor has been clinically utilized to appropriately select adjuvant chemotherapy for patients with estrogen receptor (ER)-positive early breast cancer. However, the selection of chemotherapy for patients with intermediate RSs remains controversial. We assessed the prognostic value of a 70-gene signature (70GS) among patients with ER-positive breast cancer and intermediate RSs. In addition, we sought to identify genes associated with poor 70GS scores based on gene expression profiling (GEP). GEP was performed using gene expression data from 186 patients with ER-positive breast cancer. The RS and 70GS score were calculated on the basis of GEP. Among 186 patients, 82 ER-positive patients with intermediate RSs were identified. These patients were stratified by 70GS, overall survival (OS) significantly differed according to 70GS (p = 0.013). In a supervised hierarchical analysis according to 70GS, the expression of several representative genes for cell proliferation was significantly higher in the poor 70GS cluster than in the good 70GS cluster. Furthermore, among these patients, FOXM1, AURKA, AURKB, and BIRC5 displayed prognostic significance for OS. In conclusion, 70GS can help to discriminate survival differences among ER-positive patients with intermediate RSs. FOXM1, AURKA, AURKB, and BIRC5, are associated with poor 70GS scores.",
author = "Ahn, {Sung Gwe} and Lee, {Hak Min} and Lee, {Hak Woo} and Lee, {Seung Ah} and Lee, {Se Ra} and Leem, {Sun Hee} and Jeong Joon and Chu, {In Sun}",
year = "2013",
month = "12",
day = "4",
doi = "10.3390/ijms141223685",
language = "English",
volume = "14",
pages = "23685--23699",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score. / Ahn, Sung Gwe; Lee, Hak Min; Lee, Hak Woo; Lee, Seung Ah; Lee, Se Ra; Leem, Sun Hee; Joon, Jeong; Chu, In Sun.

In: International journal of molecular sciences, Vol. 14, No. 12, 04.12.2013, p. 23685-23699.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score

AU - Ahn, Sung Gwe

AU - Lee, Hak Min

AU - Lee, Hak Woo

AU - Lee, Seung Ah

AU - Lee, Se Ra

AU - Leem, Sun Hee

AU - Joon, Jeong

AU - Chu, In Sun

PY - 2013/12/4

Y1 - 2013/12/4

N2 - The Oncotype DX® recurrence score (RS) predictor has been clinically utilized to appropriately select adjuvant chemotherapy for patients with estrogen receptor (ER)-positive early breast cancer. However, the selection of chemotherapy for patients with intermediate RSs remains controversial. We assessed the prognostic value of a 70-gene signature (70GS) among patients with ER-positive breast cancer and intermediate RSs. In addition, we sought to identify genes associated with poor 70GS scores based on gene expression profiling (GEP). GEP was performed using gene expression data from 186 patients with ER-positive breast cancer. The RS and 70GS score were calculated on the basis of GEP. Among 186 patients, 82 ER-positive patients with intermediate RSs were identified. These patients were stratified by 70GS, overall survival (OS) significantly differed according to 70GS (p = 0.013). In a supervised hierarchical analysis according to 70GS, the expression of several representative genes for cell proliferation was significantly higher in the poor 70GS cluster than in the good 70GS cluster. Furthermore, among these patients, FOXM1, AURKA, AURKB, and BIRC5 displayed prognostic significance for OS. In conclusion, 70GS can help to discriminate survival differences among ER-positive patients with intermediate RSs. FOXM1, AURKA, AURKB, and BIRC5, are associated with poor 70GS scores.

AB - The Oncotype DX® recurrence score (RS) predictor has been clinically utilized to appropriately select adjuvant chemotherapy for patients with estrogen receptor (ER)-positive early breast cancer. However, the selection of chemotherapy for patients with intermediate RSs remains controversial. We assessed the prognostic value of a 70-gene signature (70GS) among patients with ER-positive breast cancer and intermediate RSs. In addition, we sought to identify genes associated with poor 70GS scores based on gene expression profiling (GEP). GEP was performed using gene expression data from 186 patients with ER-positive breast cancer. The RS and 70GS score were calculated on the basis of GEP. Among 186 patients, 82 ER-positive patients with intermediate RSs were identified. These patients were stratified by 70GS, overall survival (OS) significantly differed according to 70GS (p = 0.013). In a supervised hierarchical analysis according to 70GS, the expression of several representative genes for cell proliferation was significantly higher in the poor 70GS cluster than in the good 70GS cluster. Furthermore, among these patients, FOXM1, AURKA, AURKB, and BIRC5 displayed prognostic significance for OS. In conclusion, 70GS can help to discriminate survival differences among ER-positive patients with intermediate RSs. FOXM1, AURKA, AURKB, and BIRC5, are associated with poor 70GS scores.

UR - http://www.scopus.com/inward/record.url?scp=84889597716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889597716&partnerID=8YFLogxK

U2 - 10.3390/ijms141223685

DO - 10.3390/ijms141223685

M3 - Article

VL - 14

SP - 23685

EP - 23699

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

ER -